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ABSTRACT 
Background: Ar-BVMO is a recently discovered Baeyer-Villiger monooxygenase from the 
genome of Acinetobacter radioresistens S13 closely related to medically relevant 
ethionamide monooxygenase EtaA (prodrug activator) and capable of inactivating the 
imipenem antibiotic. 
Methods: The co-substrate preference as well as steady-state and rapid kinetics studies of the 
recombinant purified protein were carried out using stopped-flow spectroscopy under 
anaerobic and aerobic conditions. Kd values were measured by isothermal calorimetry. 
Enzymatic activity was determined by measuring the amount of product formed using high 
pressure liquid chromatography or gas chromatography. Site-directed mutagenesis 
experiments were performed to decipher the role of the active site arginine-292.  
Results: Ar-BVMO was found to oxidize ethionamide as well as linear ketones. Mechanistic 
studies on the wild type enzyme using stopped-flow spectroscopy allowed for the detection of 
the characteristic oxygenating C4a-(hydro)peroxyflavin intermediate, which decayed rapidly 
in the presence of the substrate. Replacement of arginine 292 in Ar-BVMO by glycine or 
alanine resulted in greatly reduced or no Baeyer-Villiger activity, respectively, demonstrating 
the crucial role of this residue in catalysis of ketone substrates. However, both the R292A and 
R292G mutants are capable of carrying out N- and S-oxidation reactions. 
Conclusions: Substrate profiling of Ar-BVMO confirms its close relationship to EtaA; 
ethionamide is one of its substrates. The active site Arginine 292 is required for its Baeyer-
Villiger activity but not for heteroatom oxidation. 
General Significance: A single mutation converts Ar-BVMO to a unique S- or N-
monooxygenase, a useful biocatalyst for the production of oxidized metabolites of human 
drug metabolizing enzymes.   
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1. Introduction 
Baeyer-Villiger monooxygenases (BVMOs) are flavin-containing enzymes that mediate 
specific Baeyer-Villiger oxidations on the carbonyl moiety of their substrates. These proteins 
have great value in the conversion of ketones into corresponding esters and lactones, with 
wide applications in bioremediation and sustainable biocatalysis. In addition to Baeyer-
Villiger oxidations, BVMO enzymes can also catalyze heteroatom oxidations (nitrogen and 
sulfur) [1] that can have interesting applications to the pharmaceutical industry, as shown by 
our recent results on the oxidation of the antibiotic imipenem [2].  
All BVMO enzymes contain a flavin prosthetic group crucial for their activity, and they 
use either NADH or NADPH as the electron donor. BVMOs are abundant in bacteria, fungi, 
and plants but their numbers are limited or zero in animal or human genomes, although it has 
recently been discovered that some human flavin-containing monooxygenases, such as 
FMO5, are capable of catalyzing a Baeyer-Villiger oxidation reaction [3].  
All BVMO enzymes characterized to date are able to incorporate one atom from 
molecular oxygen into the substrate while converting the other oxygen into water [4]. The 
catalytic mechanisms are similar to those previously described in the literature for other 
flavin-containing oxygenases. In the first step of the catalytic cycle, the cofactor undergoes a 
2-electron reduction supposedly via hydride ion transfer from NAD(P)H. The reduced flavin 
reacts rapidly with molecular oxygen to form a peroxyflavin that is stabilized by the bound 
NAD(P). After a suitable substrate enters the active site of the enzyme, the flavin peroxide 
attacks the electrophilic carbonyl of the substrate, resulting in one atom of molecular oxygen 
being transferred to the substrate with the other forming water. The formation of the reactive 
peroxyflavin is independent of substrate binding, distinguishing BVMO enzymes from other 
flavin-containing hydroxylases and cytochromes P450. In the reaction, the nucleophilic attack 
of the flavin peroxide on the carbonyl group of the substrate forms a tetrahedral species that 
is known as a Criegee intermediate, and this rearranges to form an ester that is 
stereochemically imposed by the enzyme. The product then leaves the active site followed by 
the release of the NAD(P)+ and the cycle can start over again [4-6].  
The first BVMO to be studied in detail was cyclohexanone monooxygenases (CHMO) 
from Acinetobacter sp. (NCIMB 9871) [7,8]. Although the genus Acinetobacter has been 
shown to be a source of several BVMO proteins, many of these enzymes are not available in 
recombinant form and therefore have not yet been characterized. Using sequence homologies 
and the presence of the conserved Baeyer-Villiger sequence motif, we have recently 
discovered a novel BVMO, Ar-BVMO, in the genome of Acinetobacter radioresistens S13 
[9]. This protein was found to share a 49.7% sequence identity and 71.0% sequence similarity 
with the ethionamide-activating (EtaA) BVMO from Mycobacterium tuberculosis [10-12]. 
Furthermore, phylogenetic analysis of the Ar-BVMO not only placed this protein in the same 
branch as EtaA but also showed it to be closely related to the phase-1 drug metabolizing 
enzyme, human flavin-containing monooxygenase 3 (FMO3), but only distantly related to 
other canonical bacterial BVMO proteins [9,13]. Considering these relationships, initially we 
studied Ar-BVMO for its possible activities with “unusual/ non-typical” substrates and 
demonstrated that it is not only capable of oxidizing two anticancer drugs metabolized by 
human FMO3, Danusertib and Tozasertib [14,15], but it can also oxidize other synthetic 
drugs such as Imipenem [2]. Imipenem is a carbapenem, which is a clinically important 
antibiotic family used in the treatment of MultiDrug-Resistant (MDR) bacterial infections. 
Interestingly, an identical gene to that of Ar-BVMO also exists in Acinetobacter Baumannii, 
one of the so-called superbugs [2]. In these cases, Ar-BVMO seems to be responsible for the 
de-activation of this antibiotic, and therefore it acts more like a drug metabolizing enzyme. 
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Chen and coworkers [16] have also shown that a FMO from Methylocella silvestris is able to 
oxidize trimethylamine, which is also a typical substrate of eukaryotic FMO enzymes. The 
reason(s) why prokaryotic flavin monooxygenases should metabolize substrates that are 
typically metabolized by the eukaryotic FMO enzymes but not present in prokaryotic natural 
habitats is still not clear.  
In order to better understand these observations, we have undertaken the characterization 
of the wild type and mutant recombinant Ar-BVMOs. Kinetic studies of Ar-BVMO, as well 
as investigations into the roles of its active site amino acids thought to be important for BV 
reactions were carried out. Comparisons of these properties with those of canonical BVMO 
enzymes were used to try to understand how Ar-BVMO is competent to carry out 
oxygenations with synthetic and medically relevant drugs.  
The role of the active site arginine 292 was also investigated in relation to the enzyme 
activity towards linear ketones. Two mutants R292A and R292G have no BV activity while 
still maintaining their S- and N- oxygenation capabilities. These monooxygenation activities 
are important for human drug metabolism, and therefore, these Ar-BVMO mutants could be 
useful as bacterial biocatalysts for large-scale production of human drug metabolites.  
2. Materials and methods 
   2.1. Reagents 
Riboflavin, NADPH, NADH, ethionamide, 4-phenyl-2-butanone, phenethyl acetate, 2-
octanone, hexyl acetate, 2-decanone, octyl acetate, 2-decanone, methyl undecanoate, decyl 
acetate, acetonitrile, ethyl acetate, methanol, n-hexane, and salts were purchased from 
Sigma–Aldrich (Italy). 
 
   2.2. Cloning of Ar-BVMO gene in pT7 expression vector 
A. radioresistens S13 was isolated from soil surrounding an activated sludge pilot plant 
(Torino, Italy) and its Ar-BVMO gene was previously isolated by our group from A. 
radioresistens S13 genome by PCR using two primers designed on the basis of the almA gene 
of this species [13]. The product of this PCR was used as the template for the insertion of the 
desired restriction sites upstream and downstream of the gene for cloning into pT7-7 [17,18].  
The BVMO gene was amplified with a nested PCR using primers specifically designed on the 
basis of the Ar-BVMO coding gene, adding a 6 histidine tag at the C-terminus for ease of 
purification. The sequences of the primers used were: 5’-
AACCAACCAAGGATCCATGGATAAACACATTGATGTTCTAATT-3’ and 5’-
TTGGTTGGTTGAATTCTTAATGGTGATGGTGATGGTGTGAAACCAGTTTAGGTTT
ACGTTC-3’. The PCR conditions were as follows: denaturation at 94 °C for 3 min; 30 
cycles at 94 °C for 30 s, 64 °C for 30 s, and 72 °C for 1 1/2 min; and a final extension at 
72 °C for 10 min. A PCR product of the expected size (1541 bp) was obtained. The PCR 
product was digested with EcoRI and BamHI restriction enzymes. The linearized insert and 
pT7-7 vector [17,18], with compatible sticky ends, were used in a ligation reaction to produce 
the desired clone. Escherichia coli BL21 (DE3) competent cells were then transformed with 
the ligation mixtures and plated on LB agar with 100 µg/ml ampicillin. Colonies with the 
insert were screened and subsequently the entire pT7-BVMO sequenced. 
 
   2.3. Expression of wild-type Ar-BVMO  
The expression of the Ar-BVMO enzyme was carried out in a 5 L Biostat A plus fermenter. 
Forty ml of overnight liquid culture of E. coli BL21 (DE3) cells transformed with pT7-
BVMO were used to inoculate 4 L LB medium supplemented with ampicillin (100 µg/ml) 
and riboflavin (20 mg/L). The cells were grown at 37 °C and 200 rpm until OD600 of 0.5 was 
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reached. At this point, protein expression was induced by the addition of IPTG and the 
temperature was lowered to 24 °C. The cells were harvested 20 h post-induction by 20 min 
centrifugation at 4000 rpm at 4 °C.  
 
   2.4. Purification of wild-type Ar-BVMO  
All purification procedures were carried out at 4 ºC. The pellet was resuspended in 50 ml of 
Buffer A (50 mM KPi pH 7.4, 20% glycerol, 5 mM β- mercaptoethanol) supplemented with 
0.5 mM of the protease inhibitor phenylmethylsulfonyl fluoride (PMSF) and 1 mg/ml of 
lysozyme. The resuspended cells were disrupted by sonication. The lysate was supplemented 
with 1% Igepal (octylphenoxypolyethoxyethanol), stirred for 30 min at 4 °C to obtain 
complete homogeneity, and then centrifuged at 4000 rpm for 45 min. The clarified lysate was 
loaded onto a DEAE-Sepharose Fast-Flow column pre-equilibrated with buffer A. The bound 
BVMO protein was extensively washed with the same buffer before it was eluted by applying 
a gradient of 0-250 mM NaCl also in buffer A. Fractions containing the flavoprotein were 
then pooled and loaded on a Nickel chelating Sepharose Fast-Flow column pre-equilibrated 
with Buffer B (Buffer A supplemented with 250 mM NaCl). The bound protein was washed 
with 5 column volumes of Buffer B, 5 column volumes of Buffer B supplemented with 1 mM 
histidine and 2 column volumes of Buffer B supplemented with 5 mM of histidine. The 
protein was finally eluted with Buffer B supplemented with 40 mM histidine. Fractions 
presenting the characteristic FAD peaks were pooled and buffer exchanged with Amicon 
centrifugal units (30 kDa cut off) with 100 mM potassium phosphate buffer pH 7.4, 20% 
glycerol.  
 
   2.5. Determination of the extinction coefficient of Ar-BVMO 
Ar-BVMO was purified as a bright yellow protein containing the flavin cofactor. Spectral 
analysis of the purified recombinant protein displayed the characteristic flavin spectrum with 
absorbance maxima at around 375 and 450 nm. The absorbance ratio 280:450 nm of the 
purified protein was around 10.  
Following the method described by Sheng et al. [8], the purified Ar-BVMO was 
denatured in the presence of 0.1% SDS and the concentration of free FAD released from the 
enzyme was determined from its extinction coefficient of 11,300 M-1cm-1 at 450 nm [19].  
Using this procedure the extinction coefficient of Ar-BVMO was determined to be 13,900 
M-1cm-1 at 450 nm.  
The total amount of protein was also estimated using the Bradford assay and was found to 
be very similar to the estimated concentration of protein using the above extinction 
coefficient, indicating that the protein is fully occupied with FAD. The purity of the sample 
was estimated from a SDS-PAGE gel stained with Coomassie blue. 
 
   2.6. Product detection: HPLC and GC analysis 
All separations were performed using pure analytical standards of Ethionamide, 
Ethionamide-SO, 4-phenyl-2-butanone, phenethyl acetate, 2-octanone, hexyl acetate, 2-
decanone, octyl acetate, 2-dodecanone, methyl undecanoate, decyl acetate. Known 
concentrations of analytical standards were also used to quantify the product formation. 
HPLC analysis was performed with an Agilent 1200 quaternary pump HPLC System (Agilent 
Technologies, Italy) with a C18 reverse phase column (LiChroCART 250-4 column packed 
with Lichrosphere RP C18 5 µM). Previously published methods to separate Ethionamide, 
Ethionamide-SO, Tozasertib and Tozasertib NO were used [2, 9].  
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The GC analyses were performed with a 7890A GC System (Agilent Technologies, Italy) 
with a DB-Wax column (Length 30 m; Diameter 0.320 mm; PEG film 0.25 µM). The 4-
phenyl-2-butanone and phenethyl acetate were separated following a published protocol [9]. 
The separation method of 2-octanone and hexyl acetate consisted in the following steps: 
Oven start at 50 °C; to 80 °C at 10 °C/min; to 230 °C at 25 °C/min; to 250 °C at 20 °C/min; 
250 °C hold 5 min; the carrier gas was He (at 3 ml/min). The FID (Flame Ionization 
Detector) was set at 275 °C. Using this method, the retention times were found to be 5.3 min 
and 5.1 min for 2-octanone and hexyl acetate, respectively.  
The method to separate the 2-decanone and octyl acetate consisted of the following steps: 
Oven start at 100 °C; to 250 °C at 10 °C/min. The carrier gas was He (at 3 ml/min) and the 
FID (Flame Ionization Detector) was set to 275 °C. The retention times were 4.5 min and 4.2 
min, respectively. 
The method to separate the 2-dodecanone, methyl undecanoate and decyl acetate 
consisted in the following steps: Oven start at 100 °C; to 250 °C at 10 °C/min. The carrier gas 
was He (at 3 ml/min) and the FID (Flame Ionization Detector) was set at 275 °C. The 
retention times were 6.5 min, 6.4 min and 6.2 min, respectively. 
 
   2.7. Steady state parameters 
The steady state kinetic parameters for 4-phenyl-2-butanone, 2-octanone, 2-decanone and 
2-dodecanone were determined spectrophotometrically by monitoring the NADPH 
consumption rates (AU/s) at 340 nm with a series of concentrations of substrates. Samples in 
a total volume of 0.5 ml contained 0.5 µM enzyme and 150 µM of co-substrate. Reactions 
were carried out for 5 min at 30 °C in 50 mM potassium phosphate buffer, pH 7.4.  
The steady-state kinetic parameters for ethionamide or tozasertib as substrate were 
obtained using HPLC methodology as described above, with the reactions carried out at 37 
°C. 
 
   2.8. Mechanistic studies 
A Hi-Tech scientific SF-61 (TgK scientific, UK) single mixing stopped-flow system 
equipped with a diode array detector was used for the mechanistic studies. All experiments 
were performed in 50 mM potassium phosphate buffer pH 7.4, at 15 °C in a glove box (Belle 
Technologies, UK) which maintained an O2 concentration below 10 ppm. Anaerobic 
reduction of the FAD cofactor of the BVMO enzyme by NADPH/NADH was followed in the 
stopped-flow apparatus. Each shot mixed 50 µl of purified enzyme (50 µM) with 50 µl of 
buffer supplemented with NADPH or NADH (100 µM); thus, samples were diluted by half in 
the mixing cell during the kinetic measurements. Normalized 450 nm absorbance values were 
fitted with SigmaPlot 9 software to exponential decay equations with 3 parameters (y = y0 + 
ae-bx) where b represents the measured relaxation rate.  
Re-oxidation experiments were performed as follows: first, the BVMO enzyme was fully 
reduced with NADPH (1 equivalent) or sodium dithionite in anaerobiosis. The completely 
reduced enzyme in the stopped-flow apparatus was then mixed with an equal volume of 
oxygenated buffer or with oxygenated buffer containing 1000 µM of the substrate 
benzylacetone. Each shot was followed for 500 s for the co-substrate reduced enzyme and 9.6 
s for the sodium dithionite reduced enzyme. Normalized 450 nm absorbance values were 
fitted with SigmaPlot 9 software using exponential rise to maximum equations with 3 
parameters (y = y0 + a(1 - e-bx)) where b is the measured rate. 
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2.9. Isothermal calorimetry (ITC) 
ITC experiments were performed with an ITC-200 calorimeter (Malvern Instruments, 
Worcestershire, UK). The volume of the calorimetric cell was 0.2 ml, and the titrations were 
conducted by adding the titrant in steps of 1 µl. Experiments were performed at 25 °C with a 
180 s initial delay. All solutions were thoroughly degassed to prevent bubble formation in the 
cell due to stirring. Freshly prepared Ar-BVMO was dialyzed extensively against degassed 
buffer containing 50 mM potassium phosphate (pH 7.4 at 4 °C). The protein and NADP 
concentrations were 8 µM and 800 µM, respectively. Ligand solution was prepared in the 
flow-through of the dialyzed protein samples. Protein and ligand samples were quickly pre-
incubated to the required temperature using a ThermoVac (Malvern Instruments) and loaded 
in the calorimetric cell and titration syringe, respectively. The titration cell was stirred 
continuously at 700 rpm. The binding isotherms were best fit to a one-set binding site model 
by Marquardt nonlinear least-squares analysis to obtain the binding stoichiometry (N), 
association constant (KA), and thermodynamic parameters of the interaction using ORIGIN 
software, Version 7 (Malvern Instruments).  
 
2.10. H2O2  measurement 
The Amplex Red assay (Thermo Fisher Scientific) was used to quantify the H2O2 produced. 
Incubations contained 100 µM NADPH, 1 mM Benzylacetone and 10 nM purified Ar-
BVMO. Samples and standards were analyzed in 96 well plates (50 µl/well). A working 
solution of 100 mM Amplex Red reagent, 0.2 U/ml horseradish peroxidase, 50 mM sodium 
phosphate pH 7.4 added to each well in a 1:1 volume and incubated 60 min at 37 °C. The 
absorbance at 340 nm (NADPH consumption) and 572 nm (H2O2 formation) was measured 
for 1 h at 30 sec time intervals.   
 
   2.11. Site-directed mutagenesis 
The primers used for the site-directed mutagenesis were:  
Forward-R292G: 5'GCTATAATCCATGGGATCAAGGCCTTTGTGTAGTGC-3',  
Reverse-R292G: 5'GCACTACACAAAGGCCTTGATCCCATGGATTATAGC-3',  
Forward-R292A: 5'GCTATAATCCATGGGATCAAGCCCTTTGTGTAGTGC-3' and  
Reverse-R292A: 5'GCACTACACAAAGGGCTTGATCCCATGGATTATAGC-3'. 
PCR reactions were carried out in a final volume of 20 µl containing: 0.25 µM of each 
primer; 0.4 µl of template (50 ng/ µl of pT7-BVMO vector), 1 mM MgSO4, 0.2 mM dNTPs, 
2 µl of 10X KOD Buffer (Merck, Germany), 0.02 U of KOD Hot Start DNA polymerase 
(Merck, Germany). The PCR reactions were performed using a Techne TC-312 thermal 
cycler (Bibby Scientific Limited, UK) with the following sequence: denaturation at 95 °C for 
2 min; 30 cycles at 95 °C for 1 min, 55 °C for 1 min and 70 °C for 2 min and 30 s; this was 
followed by a final extension at 70 °C for 5 min. PCR products were digested for 2 h at 37 °C 
with DpnI enzyme (Fermentas) to eliminate parental DNA. E. coli DH5α competent cells 
were subsequently transformed with the DpnI-digested PCR product. The transformation 
reactions were plated onto agar plates supplemented with ampicillin (100 µg/ml). Plates were 
incubated at 37 °C for 16 h. The colonies were initially screened for the presence of the 
BVMO gene and, the R292G and R292A mutations were confirmed by DNA sequencing. 
The two mutants were expressed and purified with the WT-Ar-BVMO protocols described 
above.  
 
   2.12. Activity assay of the mutants  
For all three enzymes (WT Ar-BVMO, R292G, R292A) the reactions were performed 
with the same concentrations of each substrate in 50 mM potassium phosphate buffer pH 7.4. 
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For ethionamide, the reactions were performed in a final volume of 200 µl with 0.25 µM 
enzyme, 500 µM NADPH, and followed for 10 min at 37 °C. For 2-octanone, the reactions 
were performed for 30 min at 37 °C in a final volume of 500 µl with 0.2 µM enzyme and 200 
µM NADPH. For 4-phenyl-2-butanone, the reactions were performed for 30 min at 37 °C in a 
final volume of 500 µl with 0.1 µM enzyme and 200 µM NADPH. 
 
3. Results and Discussion 
The newly discovered Ar-BVMO was heterologously expressed, purified, and characterized 
with respect to substrate and cofactor preferences, reaction intermediates and involvement of 
the active site R292 to the overall catalysis. 
   3.1. Cloning, expression and purification of recombinant Ar-BVMO 
The ORF of the putative protein (1491 bp) was amplified via PCR using primers with the 
restriction sites of BamHI and EcoRI. The amplified construct was cloned into the pT7 
expression vector using the same two restriction sites [17,18] and finally sequenced to 
confirm the correct, in frame insertion of the gene. Escherichia coli BL21 (DE3) was chosen 
as expression system and was transformed with the pT7-BVMO construct. Preliminary 
expression was carried out in flasks before the process was scaled-up to a 5 L fermenter. An 
expression time course was carried out to determine the best time for maximal Ar-BVMO 
protein expression. A clear overexpressed band at the appropriate molecular weight of 57 
kDa was observed on SDS-PAGE gel starting from 2 h post-induction with IPTG (data not 
shown). However, maximal protein production was found to be at 20 h post-induction. 
In order to investigate the cellular localization of the protein, the DAS server (Dense 
Alignment Surface method) was used to predict the local hydrophobicity of the protein, 
confirming the absence of any transmembrane domains (Fig. 1A) [20]. The primary sequence 
of the BVMO enzyme was deduced in silico from the ORF of the gene using the Translate 
tool of ExPASy Proteomics Server [21] and consisted of 502 amino acids (including the 
engineered 6 histidine tag at the C-terminus) with a predicted molecular weight of 57 kDa. 
 
 While the E. coli BL21 expression system is optimal for a fast and high yield expression 
of proteins, it can also lead to both misfolded protein in inclusion bodies and enzymes 
predominantly in the apo-form. To overcome these problems and to increase both the yield 
and quality of the final recovered protein, the post-induction temperature was lowered to 24 
°C. The majority of the recombinant Ar-BVMO protein was found in the cytosolic fraction 
but the addition of Igepal (a nonionic, non-denaturing detergent) increased the final yield of 
the purified recombinant holo-enzyme by ~ 30%. Despite the in silico prediction of being 
cytosolic, Ar-BVMO probably has some local hydrophobic surface patches that render it 
membrane-associated, similarly to the EtaA BVMO of Mycobacterium tuberculosis [11], 
since in the absence of the nonionic Igepal from the purification buffers less protein was 
recovered.  
The recombinant Ar-BVMO was purified using two chromatography columns: first, a 
DEAE column and second, a Ni-affinity resin that tightly retained the protein due to 
engineered His-tag at the C-terminus. The eluted protein from this latter resin led to nearly 
100% pure protein as deduced from a Coomassie blue stained SDS-PAGE gel that revealed a 
single band at approximately 57 kDa, in agreement with the in silico prediction (Fig. 1B). 
The final yield of the pure protein was 8 ± 2 mg per liter of culture and was calculated based 
on the extinction coefficient of the protein at 450 nm (13,900 M-1 cm-1) together with the 
Bradford protein assay. 
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   3.2. Search for Ar-BVMO substrates 
Because the sequence of Ar-BVMO is more closely related to that of EtaA than other 
known BVMO enzymes [9], known substrates of EtaA from M. tuberculosis [12] were 
initially considered. Therefore, the EtaA substrates, 2-octanone, 2-decanone and 2-
dodecanone, were selected and following incubation with purified Ar-BVMO they were 
found to be converted into hexyl acetate, octyl acetate and a mixture of methyl undecanoate 
(8 ± 1%) and decyl acetate (92 ± 1%), respectively. The corresponding GC traces of the 
controls together with the reaction products are shown in Figure 2. 
 
The steady-state kinetic parameters for the conversion of 2-octanone and 2-decanone by 
purified Ar-BVMO were determined spectrophotometrically at 340 nm to monitor the 
NADPH consumption rates. Apparent Michaelis constants (Km) values of 351 ± 60 µM and 
66 ± 11 µM together with turnover rates (kcat) of 1.3 s-1 and 1.6 s-1 were calculated for 2-
octanone and 2-decanone, respectively. The steady-state kinetics data are summarized in 
Table 1. Incubations were performed with concentrations of substrate between 0-3 mM. As 
can be seen in the Table 1, the best substrate among those tested is 2-decanone with a 
catalytic efficiency of 2.4 x 104 M-1s-1.  Steady-state kinetic parameters of Ar-BVMO were 
also measured in the absence of substrate where it displayed a basal NADPH oxidase activity 
with a kcat value of 0.09 s-1 and a Km of 14 µM. 
The Km values measured for all these substrates were in the micromolar range with kcat 
values comparable to those reported for other previously studied BVMO enzymes [4,22]. As 
can be seen in the above table, all of the turnover rates (kcat) for the tested substrates are quite 
similar but the Km values differ. Similar observations have been made in other BVMOs [4,8], 
suggesting that the maximal turnover rate does not depend on the reactivity of the flavin 
intermediate with the substrate but rather the release of NADP+ in the final step of the 
catalytic cycle. As a consequence, the release of NADP+ limits the turnover number. In order 
to test whether Ar-BVMO turnover is also limited by the NADP+ release, the affinity of the 
enzyme for the oxidized form of NADP+ was measured using ITC. As expected, Ar-BVMO 
showed a high affinity for the oxidized cofactor (Figure 3) with a calculated Kd value of 8.3 
µM. 
 
   3.3. Ar-BVMO reduction with NADH and NADPH 
For the Group B flavoprotein monooxygenases [23], including BVMO enzymes, the 
reduction of the FAD by the co-substrate occurs in a substrate independent manner [24,25]. It 
is also known that class I BVMOs are specific for NADPH and not NADH as the electron 
donor for catalysis [5]. Stopped-flow experiments of the reductive half-reactions of Ar-
BVMO where carried out using each of the two co-substrates. Although both NADPH and 
NADH reduced the enzyme, NADPH was somewhat faster in reducing the FAD group. 
Reactions with both co-enzymes are biphasic (Fig. 4) and were fitted to a double exponential 
corresponding to a fast and a slow rate. The calculated fast reduction rates were 12.8 ± 2.0 s-1 
and 21.2 ± 4.0 s-1 with calculated slow rates of 0.15 ± 0.03 and 0.16 ± 0.01 for NADH and 
NADPH, respectively. This observed biphasic nature of the reduction rates is most probably 
due to some residual oxygen in the system. 
This difference is likely due to a more favored binding between NADPH and BVMO. To 
confirm if the reduction of Ar-BVMO by each co-enzyme subsequently led to oxygenation, 
reactions were performed with each of the co-enzymes using 4-phenyl-2-butanone as 
substrate. The ester product, phenethyl acetate, analyzed by GC, was only observed in good 
yields with NADPH as reductant, suggesting that in contrast to NADP+, NAD+ does not bind 
tightly to the reduced enzyme. 
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   3.4. Measurement of the C4a-(hydro)peroxyflavin intermediate 
 
The oxidative half-reaction of Ar-BVMO was studied by stopped-flow techniques in an 
anaerobic glove box. The enzyme was reduced by 1 equivalent of NADPH in one syringe and 
then mixed with air-saturated buffer (50 mM potassium phosphate buffer, pH 7.4) from the 
second syringe. Figure 5A shows that the formation of the the C4a-(hydro)peroxyflavin 
intermediate at 375 nm requires ~ 40 sec to be complete. This contrasts with CHMO, which 
forms the C4a-intermediate within the dead time of the stopped-flow instrument, 1-2 ms [8]. 
The intermediate then decays as shown by the increase in absorbance at 450 nm (Fig. 5A) in 
a time scale longer than 300 sec.  
 
If the same re-oxidation experiments are carried out in the presence of a substrate 
(benzylacetone), the C4a-(hydro)peroxyflavin intermediate is formed within 0.5 sec (Fig. 
5B), and the re-oxidation is much faster, with conversion to the fully oxidized form being 
complete within 7 sec. The presence of the substrate accelerates the decay of the C4a-
(hydro)peroxyflavin to the oxidized FAD by ~ 30-fold. These results demonstrate that the 
reoxidation of the enzyme in the absence of an appropriate substrate is slow, and occurs in a 
time scale of >2 min with an apparent rate constant of 0.0129 ± 0.0001 s-1 (Fig. 5C) 
indicating that the decay of the C4a-(hydro)peroxyflavin is comparable to recent data 
reported for another BVMO enzyme, BVMOAf1 from Aspergillus fumigatus Af293 [26]. 
Under these conditions, the addition of a saturating concentration of the substrate (1000 µM 
benzylacetone) to the reduced enzyme increased the re-oxidation rate up to thirty-fold with 
the estimated rate constant of 0.40 ± 0.02 s-1. Therefore, in the presence of the substrate, the 
absorbance at 450 nm increases very rapidly indicating that both formation and decay of the 
intermediate are accelerated by the addition of a substrate (Fig. 5C). This finding is in line 
with other Group B flavin monooxygenases that also show a faster rate of flavin oxidation in 
the presence of a suitable substrate [27,28]. 
Previous structural as well as mutagenesis studies have concluded that the C4a-
(hydro)peroxyflavin intermediate is stabilized by NADP+ which remains bound until the last 
step of the catalytic cycle [8,29-32]. However, if this intermediate is not stabilized or the 
NADP+ binding is compromised, the uncoupling of the enzyme results in hydrogen peroxide 
release. In order to estimate the amount of any H2O2 produced by Ar-BVMO during the 
catalytic cycle the AMPLEX RED assay was performed in the presence of a saturating 
concentration of benzylacetone (Figure S1). The results show that the uncoupling of Ar-
BVMO, evaluated as the ratio between H2O2 formed and NADPH consumed, is about 7-10%, 
and that the reaction leads to the formation of 3.16 nmol of H2O2/min/nmol Ar-BVMO. 
Rauckman et al. [33] found that purified pig liver FMO (FMO1) produced superoxide anion 
radical at the rate of about 4% of the total NADPH oxidized. Tynes et al. [34] found 
hydrogen peroxide produced by the purified rabbit lung FMO (FMO2) at up to 41% of the 
total NADPH oxidized. More recently Siddens et al. [35] published data on three human 
FMOs, where the percentage of molecular oxygen consumed that appeared as H2O2 varied 
between 30 and 50% at a rate of 0.5-2.5 nmol/min/nmol FMO. However, all these uncoupling 
data are for mammalian FMO enzymes and to our knowledge no such data has been reported 
for the bacterial BVMO enzymes.  
Finally, the oxidative half-reaction of Ar-BVMO was also monitored in the absence of 
pyrnidine nucleotide by using sodium dithionite as the reductant (Fig. 6A). In this case the re-
oxidation is complete within 9.6 sec, much faster than that observed with NADPH as the 
electron donor. Moreover, no C4a-flavin peroxide is observed, and the re-oxidation rate is not 
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dependent on the presence of the substrate; re-oxidation rates in the absence/presence of 
substrate were: 0.39 ± 0.02 s-1 versus 0.43 ± 0.02 s-1 (Fig. 6B). As mentioned earlier, the latter 
nearly identical rates were expected and in line with other BVMO and FMO enzymes where 
in normal catalysis the NADP+ remains bound and stabilizes the C4a-intermediate. Therefore, 
NADPH plays a dual role both as a reductant and in its oxidized form, a promoter of 
oxygenation, whereas dithionite is solely a flavin reductant.  
 
 
   3.5. Identification of the catalytically determinant R292 
In the absence of a crystal structure and in order to investigate the putative active site of Ar-
BVMO, a multi-alignment was performed with amino acid sequences of different BVMOs 
including HAPMO (P. fluorescens), PAMO (T. fusca), CHMO (Rhodococcus sp.), AlmA 
(Acinetobacter sp. DSM 17874), EtaA (M. tuberculosis H37RV) and Ar-BVMO (A. 
radioresistens S13) as shown in Figure 7. The conserved Baeyer-Villiger sequence motif 
FXGXXXHXXXW(P/D) [36] is highlighted by the purple box together with the known 
crucial catalytic conserved arginine residue (red box). This arginine corresponds to R440 in 
HAPMO, R337 in PAMO and R329 in CHMO. The marked sequence similarity between Ar-
BVMO, AlmA and EtaA is once again illustrated, as the conserved arginine is also within a 
conserved amino acid patch of around 5-10 amino acids (both upstream and downstream). 
The conserved aspartyl residue, involved in proper positioning of NADPH in the active site 
of these enzymes [29], is also highlighted in Figure 7 (D66 in PAMO, D192 in HAPMO, D58 
in CHMO and D56 in AlmA, EtaA and Ar-BVMO). 
 
The important role played by the conserved arginine in different BVMO enzymes has 
been previously demonstrated by site-directed mutagenesis. For example, replacing R440 of 
HAPMO from Pseudomonas fluorescens by an alanine resulted in an inactive enzyme [37] 
while R337 of PAMO from Thermobifida fusca replaced by either alanine or lysine still 
formed the C4a-peroxyflavin intermediate but the enzyme was unable to perform either the 
Baeyer-Villiger reaction on phenylacetone or the S-oxidation on benzyl methyl sulfide [38]. 
More recently, a high-resolution crystal structure of PAMO from T. fusca [29] explained how 
the arginine 337 of this enzyme contributes to ketone activation via hydrogen bonding to the 
carbonyl oxygen of the substrate, thus increasing the electrophilicity of the carbonyl carbon 
to enhance the nucleophilic attack by the C4a-peroxyflavin intermediate. Furthermore, the 
same researchers also suggested that this positively charged amino acid together with the 
NADP ribose moiety, compensates for the negative charge of the Criegee intermediate, hence 
stabilizing it [29].  
In order to understand whether this conserved arginine (R292) also plays an important 
role in Ar-BVMO, two mutants were designed and generated by site-directed mutagenesis: 
R292G and R292A. These mutants were expressed and subsequently purified with the same 
protocol as the WT Ar-BVMO, although with a lower yield of approximately 4 mg per liter 
of culture. These two mutants exhibited similar absorbance spectra to that of wild-type Ar-
BVMO and were able to oxidize NADPH. The thermal stability of the mutants was also 
evaluated and compared to the wild type. The observed melting temperatures for R292G and 
R292A were calculated to be 48.9 ± 0.2 °C and 49.1 ± 0.2 °C, respectively. These values are 
in good agreement with the measured Tm value of 48.6 ± 0.2 °C for recombinant wild type 
Ar-BVMO, indicating that the mutants are correctly folded and equally stable. 
The Baeyer-Villiger activities of the two mutants, R292G and R292A, were compared to 
that of the wild type Ar-BVMO enzyme using the two previously identified ketone substrates 
(4-phenyl-2-Butanone and 2-octanone) and measuring the products formed by GC. The 
results obtained are shown in Table 2 where drastically reduced Baeyer-Villiger activities of 
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both mutants toward the ketone substrates is demonstrated. In the case of R292A, no product 
was detected with either 4-phenyl-2-butanone or 2-octanone, whereas the R292G enzyme 
showed a small residual activity of 1.5% and 4.5% with the same two ketones, respectively. 
As mentioned earlier, the arginine to alanine mutations in HAPMO and PAMO also resulted 
in inactive enzymes with no Baeyer-Villiger activity [37,38]. The observed lack of Baeyer-
Villiger activity of the two mutants towards the tested ketones confirms the importance of 
this arginine residue for catalysis [29].  
 
In addition, the S-oxygenation and N-oxygenation activity of the mutant enzymes was 
also compared to that of the purified wild type Ar-BVMO using ethionamide and tozasertib 
as substrates, quantifying the S-oxide or N-oxide product by HPLC analysis. Both substrates 
are also known to be metabolized by the human flavin-containing monooxygenase 3 with the 
formation of the corresponding S- or N- oxides [13-15]. R292A and R292G mutants showed 
a residual activity of 83.9% and 43.3% respectively when compared to the wild type Ar-
BVMO for ethionamide and 60% and 5.3% residual activity for Tozasertib, as shown in 
Table 2. The fact that replacement of the conserved Arg residue with Ala or Gly exerts an 
effect on the S- or N- oxygenation reaction could mean that this residue is involved in more 
than just stabilization of the Criegee intermediate. In this specific case, the size of the amino 
acid residue seems to have a role in the S- or N- oxygenation activity since the bulkier Ala 
residue has nearly double the activity of the smaller Gly residue (83.9% versus 43.3% 
residual activity) suggesting a possible role of Ala in helping the stabilization of the 
intermediate by excluding water, which could otherwise break down the C4a-intermediate. 
The effect of the positive charge of the Arg residue is less important for the S- or N- 
oxygenation reaction, with the activity of the R292A mutant decreased by 16% and 40% for 
N- and S-oxidation, respectively. 
In summary, the data presented here confirm that the conserved arginine, R292, not only 
plays an important role in the activity of Ar-BVMO but is also crucial for its Baeyer-Villiger 
reactions. Moreover, the ability of the R292 mutants to catalyze S/N-oxidations is almost 
certainly associated with the nucleophilic nature of ketone oxygenations, versus the 
electrophilic nature of heteroatom oxidations by these enzymes. 
 
4. Conclusions 
   Baeyer-Villiger monooxygenases are FAD-dependent enzymes with broad substrate 
spectra, and in many cases they exhibit high stereospecificity. Similar to other members of 
the BVMO group of enzymes, Ar-BVMO shows a tightly but not covalently bound FAD 
cofactor that can be reduced anaerobically with NADPH. With NADP+ product remaining 
bound, the resulting FADH can react with O2 to form a flavin C4a-peroxide. This “loaded 
gun” intermediate of the enzyme can bind any of a variety of substrates, and the flavin C4a-
peroxide can effect Baeyer-Villiger reactions with carbonyl substrates or oxidations or 
oxygenations of thiols, thioethers, or amines. Ar-BVMO also seems to have broad substrate 
tolerance, which is consistent with the kinetic data presented in this work. The enzyme C4a-
(hydro)peroxyflavin intermediate is relatively stable and does not convert rapidly to oxidized 
flavin rapidly unless a suitable substrate is present. The initial reduction step by NADPH is 
independent of the substrate and not strictly controlled, presumably because it would be 
difficult to effect substrate control with the broad substrate acceptance of this enzyme.  
The role of the active site Arginine 292 residue of Ar-BVMO in catalysis was investigated 
by engineering two mutants, R292A and R292G. The R292A variant had no measureable 
activity and the R292G variant had very little activity in Baeyer-Villiger catalysis. However, 
the monooxygenation activity with the sulfur-containing substrate ethionamide by the R292A 
variant was only slightly less than that of wild type Ar-BVMO. An aurora kinase inhibitor, 
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Tozasertib, was also tested to assess the N-oxidation activity of the mutants. The R292A 
mutant retained more than 60% of the activity of the wild type enzyme. The data clearly 
show that the R292A mutant is not able to perform BV catalysis, but can selectively perform 
S- or N- oxidations similar to human flavin-containing monooxygenases.  
Finally, since Ar-BVMO can be expressed in E. coli without inhibiting the host bacterial 
growth, scaling up the expression of its mutants in fermenters can lead to high yields of these 
biocatalysts, which can be used for large-scale production of oxidized human FMO 
metabolites. 
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TABLE 1. Steady-state kinetic parameters of Ar-BVMO determined by rates of NADPH 
consumption. 
 
Substrate Reaction 
Km  kcat kcat /Km 
[µM] [s-1] [103 s-1M-1] 
Tozasertiba 
 
54 ± 8 0.11 1.95 
Ethionamidea,b 768 ± 57 0.3 0.4 
4-Phenyl-2-
Butanonea 
696 ± 322 0.3 0.4 
2-Octanone 351 ± 60 1.3 3.7 
2-Decanone 66 ± 11 1.6 24 
2-Dodecanone nd nd   
a Substrates previously identified [2,14]; 
b Km determined by quantifying the product formed using HPLC at different concentrations of 
substrate.  
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TABLE 2. Activity of the two Ar-BVMO mutants with different substrates compared to the wild type 
enzyme.  
 
                     Substrate   
BVMO 2-Octanone 4-Phenyl-2-butanone Ethionamide Tozasertib 
WT 100% 100% 100% 100% 
R292A nd* nd* 83.9% 60% 
R292G 4.6% 1.5% 43.3% 5.3% 
*not detectable 
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FIGURE LEGENDS 
 
FIGURE 1. (A) Hydropathy plot of Ar-BVMO using the DAS-TM program. (B) 10% SDS-
PAGE gel of purified Ar-BVMO: Lane 1 and 5 protein markers, Lane 2 crude extract; Lane 3 
first purification step (DEAE); Lane 4 second purification step (Ni-affinity). 
 
FIGURE 2. GC chromatograms of incubations of 2-octanone, 2-decanone and 2-dodecanone 
in the absence (A, C, E) and presence (B, D, F) of purified Ar-BVMO. 
 
FIGURE 3. Isothermal calorimetric titration of NADP (800 µM) with purified Ar-BVMO 
(12.5 µM) in 50 mM potassium phosphate buffer pH 8 at 25 °C. Heat variation generated by 
each injection of titrant at each time interval (top panel) and the integration of each peak and 
the amount of heat produced (lower panel). 
 
FIGURE 4. Ar-BVMO absorbance spectra collected during anaerobic reduction with 2 
equivalents of either (A) NADH or (B) NADPH. The experiments were performed in 50 mM 
potassium phosphate buffer pH 7.4 at 8 °C over 0.96 s at 10 ms intervals. (C) Kinetic analysis 
of the reduction of the flavin cofactor. Exponential decay fitting of the NADH (closed circles) 
and NADPH mediated reduction (open circles) fitted to a double exponential: fast reduction 
rates were 21.2 ± 4.0 s-1 and 12.8 ± 2.0 s-1 with calculated slow rates of 0.16 ± 0.01 and 0.15 
± 0.03 for NADPH and NADH, respectively. 
 
FIGURE 5. (A) Formation and decay of the C4a-(hydro)peroxyflavin within 300 sec after 
mixing the NADPH reduced enzyme with air-saturated buffer (without substrate); (B) 
Formation and decay of the C4a-(hydro)peroxyflavin within 7 sec after mixing the NADPH 
reduced enzyme with air-saturated buffer (with 1000 µM benzylacetone). (C) Comparison of 
the decay of the C4a-(hydro)peroxyflavin in the presence (red line) and absence of 
benzylacetone substrate (blue line) followed at 450 nm. The experiment was performed in 50 
mM potassium phosphate buffer pH 7.4 at 15 °C. 
 
FIGURE 6. A) Spectra of the re-oxidation of Ar-BVMO after complete reduction with 
sodium dithionite and mixing the reduced enzyme with air-saturated buffer. The experiment 
was performed in 50 mM potassium phosphate buffer pH 7.4 at 8 °C in a 9.6 sec time scale. 
B) Kinetic analysis of the re-oxidation of the flavin cofactor. Exponential rise to maximum 
fitting of the re-oxidation with oxygenated buffer only (filled circles) and oxygenated buffer 
with substrate (empty circles). The observed re-oxidation rate constants were 0.39 ± 0.02 s-1 
and 0.43 ± 0.02 s-1, respectively.  
 
FIGURE 7. Multi-alignment of the primary sequences of HAPMO (P. fluorescens); PAMO 
(T. fusca); CHMO (Rhodococcus sp.); Ar-BVMO (A. radioresistens S13); AlmA 
(Acinetobacter sp. DSM 17874) and EtaA (M. tuberculosis H37RV). The BVMO motif, the 
conserved arginine and aspartic acid residues are indicated by purple, red and green boxes, 
respectively.  
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Figure 7 
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Figure S1 
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